| Name | Title | Contact Details |
|---|
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
Grabber Performance Group is a Wyoming, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.
Proprio is a Seattle company developing a system for real-time immersive video and mediated reality interaction. We are using cutting edge algorithms and custom hardware to enhance human capabilities in high precision activities such as brain surgery.
For more than 85 years, the Hendrick name has been the first name in healthcare in Abilene, Texas, and the Texas Midwest. As the first healthcare network to establish a true system of services, the Hendrick name reigns over a 522-bed medical center, a women’s center, rehabilitation hospital, cancer center and numerous other innovative services. Hendrick was the first hospital to permanently serve the Texas Midwest when its doors opened in 1924. During the Great Depression, it was the first hospital people of the Big Country area rallied behind to keep the doors open when money was scarce. Mr. and Mrs. Thomas Hendrick, for whom the institution was named, made the first major financial gift to the hospital. Through the years it has been the first in the area to offer specialized services, creating departments to fill needs such as physical medicine, nuclear medicine, spiritual care and much more.